[Email id of designated official for the purpose of grievance redressal]
UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 30th JUNE, 2005 |
||||
---|---|---|---|---|
(Rs. In Lakhs) |
||||
PARTICULARS |
For the Quarter Ended on 30.06.2005 UNAUDITED |
For the Quarter Ended on 30.06.2004 UNAUDITED |
For the Year Ended 31.03.2005 UNAUDITED |
|
INCOME FROM OPERATIONS | 6938.16 |
5802.02 |
24662.24 |
|
OTHER INCOME | 10.74 |
11.99 |
1159.21 |
|
TOTAL INCOME | 6948.90 |
5814.01 |
25821.45 |
|
TOTAL EXPENDITURE | 6154.92 |
5204.97 |
21792.86 |
|
- DECREASE IN STOCK IN trADE | 263.75 |
291.68 |
1094.47 |
|
- CONSUMPTION OF RAW MATERIAL | 4987.44 |
4080.13 |
17359.44 |
|
- STAFF COST | 226.17 |
184.38 |
725.89 |
|
- OTHER EXPENSES | 677.56 |
648.78 |
2613.06 |
|
INTEREST | 196.82 |
154.03 |
682.68 |
|
DEPRECIATION | 31.52 |
24.62 |
112.92 |
|
PROFIT BEFORE TAX | 565.64 |
430.39 |
3232.99 |
|
- PROVISION FOR TAX | 42.41 |
32.28 |
163.97 |
|
- PROVISION FOR DEFERRED TAX | 2.50 |
1.04 |
257.00 |
|
NET PROFIT | 520.73 |
397.07 |
2812.02 |
|
PAID UP EQUITY SHARE CAPITAL (FACE VALUE OF RS 2/- PER SHARE)* | *727.57 |
502.5 |
727.57 |
|
RESERVES EXCLUDING REVALUATION RESERVES | ||||
EPS - Rs. NOT ANNUALISED (PAR VALUE RS 2/-PER SHARE)* | *1.43 |
7.90 |
45.98 |
|
AGGREGATE OF NON-PROMOTERS SHAREHOLDING | ||||
NUMBER OF SHARES | 23791475 |
3339443 |
4758295 |
|
% OF SHARE HOLDING | 65.40 |
66.46 |
65.40 |
|
NOTES: |
||||
1. During the Quarter ended on 30.06.2005 the net profit of the company rose by 31.14% and sales rose by 19.58% as compared to corresponding period of previous year. 2. The Company’s expansion plans involving setting up of new finished dosage facility in Jammu, a new 100% Export Oriented Unit at Lalru (Punjab) and a new facility at Baddi for the Domestic Market is at advance stage ,of completion and is expected to be operational in next 2-3 months. 3. The company had received ¬¬¬5 complaints during the quarter under review which were duly redressed to the satisfaction of the shareholders during the same quarter and as such, there were no pending complains as on 30th June 2005. 4. The company is exclusively in the pharmaceutical business segment. 5. The above financial results were taken on record by the Board in its meeting held on 30th July 2005. |
||||
On behalf of the
Board |
||||
Dated: 30.07.2005 |
(Gopal Munjal) |
|||
Place: Chandigarh |
Chairman |
|||